Tags

Type your tag names separated by a space and hit enter

The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants.
Trends Pharmacol Sci. 2009 Sep; 30(9):484-93.TP

Abstract

The endocannabinoid system is a neuromodulatory system which is known to regulate emotional, cognitive, neurovegetative and motivational processes. Substantial evidence has accumulated implicating a deficit in endocannabinoid in the etiology of depression; accordingly, pharmacological augmentation of endocannabinoid signaling could be a novel target for the pharmacotherapy of depression. Within preclinical models, facilitation of endocannabinoid neurotransmission evokes both antidepressant and anxiolytic effects. Similar to the actions of conventional antidepressants, enhancement of endocannabinoid signaling can enhance serotonergic and noradrenergic transmission; increase cellular plasticity and neurotrophin expression within the hippocampus; and dampen activity within the neuroendocrine stress axis. Furthermore, limbic endocannabinoid activity is increased by both pharmacological and somatic treatments for depression, and, in turn, appears to contribute to some of the neuroadaptive alterations elicited by these treatments. These preclinical findings support the rationale for the clinical development of agents which inhibit the cellular uptake and/or metabolism of endocannabinoids in the treatment of mood disorders.

Authors+Show Affiliations

Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19732971

Citation

Hill, Matthew N., et al. "The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants." Trends in Pharmacological Sciences, vol. 30, no. 9, 2009, pp. 484-93.
Hill MN, Hillard CJ, Bambico FR, et al. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci. 2009;30(9):484-93.
Hill, M. N., Hillard, C. J., Bambico, F. R., Patel, S., Gorzalka, B. B., & Gobbi, G. (2009). The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends in Pharmacological Sciences, 30(9), 484-93. https://doi.org/10.1016/j.tips.2009.06.006
Hill MN, et al. The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants. Trends Pharmacol Sci. 2009;30(9):484-93. PubMed PMID: 19732971.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. AU - Hill,Matthew N, AU - Hillard,Cecilia J, AU - Bambico,Francis R, AU - Patel,Sachin, AU - Gorzalka,Boris B, AU - Gobbi,Gabriella, Y1 - 2009/09/03/ PY - 2009/04/02/received PY - 2009/06/10/revised PY - 2009/06/11/accepted PY - 2009/9/8/entrez PY - 2009/9/8/pubmed PY - 2009/11/10/medline SP - 484 EP - 93 JF - Trends in pharmacological sciences JO - Trends Pharmacol. Sci. VL - 30 IS - 9 N2 - The endocannabinoid system is a neuromodulatory system which is known to regulate emotional, cognitive, neurovegetative and motivational processes. Substantial evidence has accumulated implicating a deficit in endocannabinoid in the etiology of depression; accordingly, pharmacological augmentation of endocannabinoid signaling could be a novel target for the pharmacotherapy of depression. Within preclinical models, facilitation of endocannabinoid neurotransmission evokes both antidepressant and anxiolytic effects. Similar to the actions of conventional antidepressants, enhancement of endocannabinoid signaling can enhance serotonergic and noradrenergic transmission; increase cellular plasticity and neurotrophin expression within the hippocampus; and dampen activity within the neuroendocrine stress axis. Furthermore, limbic endocannabinoid activity is increased by both pharmacological and somatic treatments for depression, and, in turn, appears to contribute to some of the neuroadaptive alterations elicited by these treatments. These preclinical findings support the rationale for the clinical development of agents which inhibit the cellular uptake and/or metabolism of endocannabinoids in the treatment of mood disorders. SN - 1873-3735 UR - https://www.unboundmedicine.com/medline/citation/19732971/The_therapeutic_potential_of_the_endocannabinoid_system_for_the_development_of_a_novel_class_of_antidepressants_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-6147(09)00121-7 DB - PRIME DP - Unbound Medicine ER -